Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have significantly changed the treatment landscape of DKD as they are highly efficacious in preventing ESKD and cardiovascular events [3–5]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.